logo-loader
viewArix Bioscience PLC

Arix notes Iterum?s proposed US IPO

/**/ OL { MARGIN-BOTTOM: 0cm } UL { MARGIN-BOTTOM: 0cm } LINK { COLOR: #000000 } visited { COLOR: fuchsia } .aj { MARGIN: 72pt; size: 595.0pt 842.0pt } DIV.aj { } P.aw { BORDER-BOTTOM-STYLE: none; TEXT-ALIGN: center; LINE-HEIGHT: 107%; BORDER-RIGHT-STYLE: none; MARGIN: 0cm; FONT-FAMILY: "Calibri","sans-serif"; BORDER-TOP-STYLE: none; COLOR: black; FONT-SIZE: 11pt; BORDER-LEFT-STYLE: none } SPAN.au { LINE-HEIGHT: 107%; FONT-FAMILY: "Arial","sans-serif"; FONT-SIZE: 10pt } P.ax { BORDER-BOTTOM-STYLE: none; TEXT-ALIGN: center; BORDER-RIGHT-STYLE: none; MARGIN: 0cm 0cm 0pt; FONT-FAMILY: "Times New Roman","serif"; BORDER-TOP-STYLE: none; FONT-SIZE: 12pt; BORDER-LEFT-STYLE: none; FONT-WEIGHT: bold } SPAN.as { FONT-FAMILY: "Arial","sans-serif"; FONT-SIZE: 10pt } P.a { BORDER-BOTTOM-STYLE: none; BORDER-RIGHT-STYLE: none; MARGIN: 0cm 0cm 0pt; FONT-FAMILY: "Times New Roman","serif"; BORDER-TOP-STYLE: none; FONT-SIZE: 12pt; BORDER-LEFT-STYLE: none } LI.a { BORDER-BOTTOM-STYLE: none; BORDER-RIGHT-STYLE: none; MARGIN: 0cm 0cm 0pt; FONT-FAMILY: "Times New Roman","serif"; BORDER-TOP-STYLE: none; FONT-SIZE: 12pt; BORDER-LEFT-STYLE: none } DIV.a { BORDER-BOTTOM-STYLE: none; BORDER-RIGHT-STYLE: none; MARGIN: 0cm 0cm 0pt; FONT-FAMILY: "Times New Roman","serif"; BORDER-TOP-STYLE: none; FONT-SIZE: 12pt; BORDER-LEFT-STYLE: none } P.ay { BORDER-BOTTOM-STYLE: none; TEXT-JUSTIFY: inter-ideograph; TEXT-ALIGN: justify; BORDER-RIGHT-STYLE: none; MARGIN: 0cm 0cm 0pt; FONT-FAMILY: "Times New Roman","serif"; BORDER-TOP-STYLE: none; FONT-SIZE: 12pt; BORDER-LEFT-STYLE: none; FONT-WEIGHT: bold } P.az { BORDER-BOTTOM-STYLE: none; TEXT-JUSTIFY: inter-ideograph; TEXT-ALIGN: justify; BORDER-RIGHT-STYLE: none; MARGIN: 0cm 0cm 0pt; FONT-FAMILY: "Times New Roman","serif"; BORDER-TOP-STYLE: none; FONT-SIZE: 12pt; BORDER-LEFT-STYLE: none } P.ba { TEXT-ALIGN: center; FONT-FAMILY: "Times New Roman","serif"; MARGIN-LEFT: 0cm; FONT-SIZE: 12pt; MARGIN-RIGHT: 0cm } SPAN.bb { FONT-FAMILY: "Arial","sans-serif"; FONT-SIZE: 10pt; FONT-WEIGHT: bold } SPAN.am { FONT-FAMILY: "Arial","sans-serif"; FONT-SIZE: 10pt } P.bc { BORDER-BOTTOM-STYLE: none; TEXT-ALIGN: center; LINE-HEIGHT: 107%; BORDER-RIGHT-STYLE: none; MARGIN: 0cm; FONT-FAMILY: "Calibri","sans-serif"; BORDER-TOP-STYLE: none; COLOR: black; FONT-SIZE: 11pt; BORDER-LEFT-STYLE: none; FONT-WEIGHT: bold } SPAN.al { LINE-HEIGHT: 107%; FONT-FAMILY: "Arial","sans-serif"; FONT-SIZE: 10pt } /**/
RNS Number : 8795M
Arix Bioscience Plc
02 May 2018
 

 

 

Arix Bioscience plc

 

Iterum announces confidential submission of draft registration statement for proposed initial public offering in the United States

 

 

2 May 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its Group Business Iterum Therapeutics ("Iterum") has submitted a registration statement on Form S-1 to the US Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of ordinary shares in the United States. Iterum has applied to list its ordinary shares on the Nasdaq Global Select Market under the symbol "ITRM." The timing and the terms of this proposed initial public offering have not yet been determined and are subject to market conditions and other factors.

ENDS

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Investor Relations Manager

+44 (0)20 7290 1072

[email protected]

 

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

[email protected]

 

 

About Arix Bioscience plc

 

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

 

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

 

 

About Iterum Therapeutics plc

 

Iterum Therapeutics plc (Iterum Therapeutics) is an Irish clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound with oral and IV formulations that has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received QIDP designations for its oral and IV formulations for the treatment of uUTI, cUTI and cIAI. Iterum Therapeutics is led by a highly experienced team and backed by a blue-chip venture capital syndicate. For more information, please visit www.iterumtx.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFIAEAIFIIT

Quick facts: Arix Bioscience PLC

Price: 96.5

Market: LSE
Market Cap: £130.81 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19